ERBB2 and breast carcinoma: Patients overexpressing HER2 classically have a poor prognosis, but since the introduction of Trastuzumab, in combination with chemotherapy, this situation has completely changed; HER2‐positive patients now have a survival rate similar to median breast cancer survival rates.53